FDA: Update on Class I Biowaivers [Dissolution / BCS / IVIVC]
Dear all,
at the
in Bad Homburg on 17-18 June 2008 Vinod Shad (FIP Scientific Secretary) reported that conditions stated in FDA's Guideline (August 2000) were relaxed following recommendations of the WHO TRS 973, Annex 7 (May 2006).
New specifications are
These changes are mainly without written documentation but have to be followed from now on. For an example where the new pH is mentioned see the recommendation on Bupropion.
For another reference see Lawrence Yu's presentation 'BCS Biowaiver Extension: Roles of Dissolution' given at the AAPS Workshop on Dissolution and QbD, April 29th, 2008.
at the
EUFEPS Network Conference on New Regulations in Bioequivalence:
Revised European CHMP Note for Guidancein Bad Homburg on 17-18 June 2008 Vinod Shad (FIP Scientific Secretary) reported that conditions stated in FDA's Guideline (August 2000) were relaxed following recommendations of the WHO TRS 973, Annex 7 (May 2006).
New specifications are
pH 1.2, 4.5 and 6.8 (instead of pH 7.4), and
relative bioavailability of 85% (instead of 90%).These changes are mainly without written documentation but have to be followed from now on. For an example where the new pH is mentioned see the recommendation on Bupropion.
For another reference see Lawrence Yu's presentation 'BCS Biowaiver Extension: Roles of Dissolution' given at the AAPS Workshop on Dissolution and QbD, April 29th, 2008.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes